loperamide has been researched along with bethanechol in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Auernhammer, CJ; Beier, G; Lehnert, P; Reichardt, B; Riepl, RL; Schopohl, J; Stalla, GK | 1 |
| Mawe, GM; Otto, B; Riepl, RL | 1 |
1 review(s) available for loperamide and bethanechol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for loperamide and bethanechol
| Article | Year |
|---|---|
Suppression of vagus-mediated pancreatic polypeptide release by the mu-opiate receptor agonist loperamide in man.
Topics: Adult; Bethanechol; Ceruletide; Corticotropin-Releasing Hormone; Humans; Loperamide; Male; Pancreatic Polypeptide; Receptors, Opioid, mu; Vagus Nerve | 1996 |
1 other study(ies) available for loperamide and bethanechol
| Article | Year |
|---|---|
mu-Opiate receptor agonist loperamide blocks bethanechol-induced gallbladder contraction, despite higher cholecystokinin plasma levels in man.
Topics: Adult; Bethanechol; Cholecystokinin; Cross-Over Studies; Gallbladder; Humans; Loperamide; Male; Muscle Contraction; Muscle, Smooth; Pancreatic Polypeptide; Placebos; Receptors, Opioid, mu | 2005 |